Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that the U.S. Patent and Trademark office has issued a new patent further strengthening Atossa's intellectual property in its proprietary therapy Endoxifen, which is under development for breast cancer and other breast conditions.

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) --  Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter and fiscal year ended December 31, 2021 and provides an update on recent company developments.

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders:

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast density, which is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide.

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

SEATTLE, Dec. 16, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses.

Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur

Camber Energy

Kosmos Energy

Are these penny stocks on your list of small-caps to watch right now? The post 3 Penny Stocks to Watch With Bullish Sentiment Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch With Bullish Sentiment Right Now

Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting

Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

Dare Bioscience

Meten Holding Group Ltd.

Check these Reddit penny stocks out for your December 2021 watchlist The post 3 Reddit Penny Stocks For Your Early December Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Reddit Penny Stocks For Your Early December Watchlist

Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO will address a series of questions regarding Atossa's research programs and future developments Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO will address a series of questions regarding Atossa's research programs and future developments

Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended September 30, 2021, and provides an update on recent company developments.

Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Global Pandemic Caused a Significant Drop In Mammograms as Clinics Remained Closed Global Pandemic Caused a Significant Drop In Mammograms as Clinics Remained Closed

Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

Bridgeline Digital

China Rapid Finance

These active penny stocks could be worth adding to your list right now The post Most Active Penny Stocks to Buy? Check These 4 Out Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Most Active Penny Stocks to Buy? Check These 4 Out Right Now

Atossa Therapeutics is clinical-stage biotech whose stock has trended a highly volatile path during the last one-year period.

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Genius Brands

Seelos Therapeutics

Reddit penny stocks are here to stay; have you heard of these three? The post Hot Penny Stocks on Reddit to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks on Reddit to Watch Right Now

GEE Group

Metromile

If you're looking for penny stocks on Reddit, check these three out first The post Top Penny Stocks on Reddit For Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks on Reddit For Your Watchlist Right Now

New York, New York--(Newsfile Corp. - September 13, 2021) -  Levi & Korsinsky announces that it has commenced an investigation of Atossa Therapeutics, Inc. (NASDAQ: ATOS) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/atossa-therapeutics-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Atossa Therapeutics, Inc. - ATOS

Denison Mines

PaySign Inc

Making a penny stocks watchlist for this coming week? Check these 3 small-caps out The post 3 Hot Penny Stocks For This Week's Small-Caps Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks For This Week's Small-Caps Watchlist

Today, investors in Atossa Pharmaceuticals and ATOS stock appear to be cheering a delayed shareholder vote on a stock issuance proposal. The post ATOS Stock Holders Should Mark Their Calendars for Oct. 7 appeared first on InvestorPlace.

ATOS Stock Holders Should Mark Their Calendars for Oct. 7

Clovis Oncology

Mind Medicine MindMed

PharmaCyte Biotech

Sesen Bio Inc.

VBI Vaccines

vTv Therapeutics

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace.

7 Penny Stocks Waiting on The FDA for Rocket Fuel

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Atossa Therapeutics Inc (NASDAQ: ATOS) has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen to reduce mammographic breast density (MBD).  Atossa plans to start enrolling participants in Q4 of 2021.

Atossa To Conduct Endoxifen Mid-Stage Study In Sweden

SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announced it has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen for the reduction of mammographic breast density (MBD). MBD is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide. Studies conducted by others have shown that MBD reduces the ability of mammograms to detect cancer and increases the risk of developing breast cancer. Additional studies show a correlation between reducing MBD and a reduction in the incidence of breast cancer.

Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

Atossa's COVID-19 treatment is too little too late and I am concerned about the market size for Endoxiden. ATOS stock should not have a $448 million market cap.

News for Atossa Genetics Stock (ATOS)